OGN - FDA accepts supplemental application for Humira biosimilar from Samsung Bioepis Organon
2023-11-08 05:28:37 ET
More on Organon
- Organon: Poor Q3 Earnings Make Bear Case, But Dividend Is Saving Grace
- Organon & Co (OGN) Q3 2023 Earnings Call Transcript
- Organon: The Federal Reserve Black Swan (Rating Upgrade)
- Goldman downgrades Organon following dismal Q3
- Organon stock plumbs all-time low on Q3 weakness in flagship women's health unit
For further details see:
FDA accepts supplemental application for Humira biosimilar from Samsung Bioepis, Organon